Around one-third of AML patients carry FLT3 duplication mutations; therefore, the results of this study are significant as the lead compounds are active against Molm-14 cell lines that carry FLT3 internal tandem duplication mutations [37]. This evidence concerns the gene FLT3 and acute myeloid leukemia.